(+)-Taxifolin

(+)-Taxifolin

SCHEMBL296323

O=C1c2c(O)cc(O)cc2O[C@@H](c2ccc(O)c(O)c2)[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 1.00
ALOX15 P16050 4/20 1.00
MAPT P10636 3/20 1.00
HSD17B10 Q99714 3/20 1.00
RECQL P46063 2/20 1.00
SOST Q9BQB4 2/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
KDM4E B2RXH2 2/20 1.00
GAA P10253 2/20 1.00
ALOX12 P18054 2/20 1.00
HIF1A Q16665 2/20 1.00
POLB P06746 1/20 1.00
CYP1A2 P05177 1/20 1.00
NFKB1 P19838 1/20 1.00
MAPK1 P28482 1/20 1.00
SYNJ2 O15056 3/20 0.75
APP P05067 1/20 0.75
XDH P47989 2/20 0.67
IDO1 P14902 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Taxifolin SCHEMBL29390633 1.00 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Taxifolin SCHEMBL30300501 1.00 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Taxifolin SCHEMBL30631315 1.00 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Taxifolin SCHEMBL29361519 1.00 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Taxifolin SCHEMBL13241264 1.00 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Taxifolin SCHEMBL7628142 1.00 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Taxifolin SCHEMBL29368246 1.00 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Epitaxifolin SCHEMBL31575455 1.00 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Taxifolin SCHEMBL1707803 1.00 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Taxifolin SCHEMBL29367955 1.00 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3681504-B1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN INC (US) 2023-08-23 EP disclosed
WO-2023069981-A1 USES OF TAXIFOLIN FOR RESPIRATORY HEALTH PHYTO TECH CORP. (US) 2023-04-27 WO disclosed
US-20230119141-A1 USES OF TAXIFOLIN FOR RESPIRATORY HEALTH PHYTO TECH CORP. 2023-04-20 US disclosed
US-11573224-B2 Methods of detection using X-ray fluorescence ICAGEN, LLC (US) 2023-02-07 US disclosed
US-20220378716-A1 FORMULATION TO REDUCE OR PREVENT OXIDATIVE STRESS DAMAGE Cora Therapeutics Inc. (CA) 2022-12-01 US disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 US disclosed
US-10877035-B2 Advanced drug development and manufacturing ICAGEN, LLC (US) 2020-12-29 US disclosed
US-20200278346-A1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ADJACENT ACQUISITION CO., LLC 2020-09-03 US disclosed
EP-3681504-A1 METHODS OF DETECTION USING X-RAY FLUORESCENCE Icagen, Inc. (US) 2020-07-22 EP disclosed
US-10292962-B2 Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer RESEARCH INSTITUTE FOR NUTRITION AND AGING CO., LTD. (JP) 2019-05-21 US disclosed
EP-2511844-A2 Advanced drug development and manufacturing Los Alamos National Security, LLC (US) 2012-10-17 EP disclosed
EP-2084519-B1 X-RAY FLUORESCENCE ANALYSIS METHOD LOS ALAMOS NAT SECURITY LLC (US) 2012-08-01 EP disclosed
EP-2427480-A1 PLANTS HAVING ENHANCED YIELD-RELATED TRAITS AND/OR ENHANCED ABIOTIC STRESS TOLERANCE AND A METHOD FOR MAKING THE SAME BASF Plant Science Company GmbH (DE) 2012-03-14 EP disclosed
WO-2010127969-A1 PLANTS HAVING ENHANCED YIELD-RELATED TRAITS AND/OR ENHANCED ABIOTIC STRESS TOLERANCE AND A METHOD FOR MAKING THE SAME BASF PLANT SCIENCE COMPANY GMBH (DE) 2010-11-11 WO disclosed
US-20100286255-A1 METHOD FOR EXTRACTING SECOISOLARICIRESINOL AND DIHYDROQUERCETIN FROM WOOD NIFANTIEV NIKOLAY EDUARDOVICH 2010-11-11 US disclosed
US-20100286255-A1 METHOD FOR EXTRACTING SECOISOLARICIRESINOL AND DIHYDROQUERCETIN FROM WOOD NIFANTIEV NIKOLAY EDUARDOVICH 2010-11-11 US disclosed
EP-2084519-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING Los Alamos National Security, LLC (US) 2009-08-05 EP disclosed
WO-2008127291-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING LOS ALAMOS NATIONAL SECURITY, LLC (US) 2008-10-23 WO disclosed
US-20080220441-A1 Advanced drug development and manufacturing THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-09-11 US disclosed
WO-2006003456-A2 GLYCOSYLATION OF ANTIBIOTICS ISIS INNOVATION LIMITED (GB) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286255-A1 METHOD FOR EXTRACTING SECOISOLARICIRESINOL AND DIHYDROQUERCETIN FROM WOOD DCXR, WFS1, DHCR7 CYP3A4 769/4885ALOX15 2002/4885MAPT 3165/4885
US-10292962-B2 Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer KRAS, VHL, HKDC1 CYP3A4 2296/4885ALOX15 4746/4885MAPT 2755/4885
US-20230119141-A1 USES OF TAXIFOLIN FOR RESPIRATORY HEALTH ACE2, MAVS, ACE CYP3A4 3248/4885ALOX15 3138/4885MAPT 1241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.